Bio-Techne stock sits 0.22 percent below its 52-week high
Published on 10/15/2026 at 18:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst view and reporting date
- The stock sat 0.22 percent below its 52-week high on October 15, 2026.
- MarketBeat counted 17 analysts in a Hold consensus on October 14, 2026.
- Bio-Techne stock costs EUR 64.71 at Lang & Schwarz on October 15, 2026 at 6:36 p.m. CEST, up 0.05 percent on Nasdaq.
- Bio-Techne lists November 3, 2026 as its next earnings date.
Bio-Techne stock sat 0.22 percent below its 52-week high on October 15, 2026, based on a Nasdaq quote of USD 72.53. At Lang & Schwarz, the euro quote was EUR 64.71 on October 15, 2026 at 6:36 p.m. CEST, up 0.05 percent on Nasdaq versus the prior close.
Analysts keep a cautious target
MarketBeat reported on October 14, 2026 that 17 analysts held a consensus Hold rating and an average 12-month target of USD 68.92. Against the USD 72.53 Nasdaq quote, that target sat 5.24 percent below the share price. The gap gives the valuation discussion a clear reference point without turning the target into a forecast.
Near the yearly high
The Nasdaq quote reached USD 72.61 at its intraday high and USD 72.50 at its low on October 15, 2026. The 52-week range was USD 43.20 to USD 72.69, placing the share 67.89 percent above its low and 0.22 percent below its high. Trading volume stood at 1,551,792 shares, compared with an average of 3,051,596 shares, or 49.15 percent lower.
For context, Bio-Techne announced on October 8, 2026 that it was expanding its global GMP manufacturing network with a new Bristol facility. The announcement adds an operating development to the market picture, while the current quote remains close to its yearly high.
Valuation and November results
Bio-Techne had a market capitalization of USD 11.4 billion and a price-to-earnings ratio of 62.53 on October 15, 2026. Its investor-relations page lists fiscal 2026 adjusted earnings per share of USD 0.52 and an adjusted operating margin of 32.20 percent for the year ended June 30, 2026. Sync2Cal lists November 3, 2026 as the next earnings date.
Comparison with peers
Bio-Techne (Nasdaq, USD): plus 0.05 percent, P/E 62.53, market capitalization USD 11.4 billion
Illumina (Nasdaq, USD): minus 1.69 percent, P/E 49.87, market capitalization USD 40.3 billion
Danaher (NYSE, USD): plus 2.99 percent, P/E 41.12, market capitalization USD 162.7 billion
Euro quote after the Xetra close
Bio-Techne's euro quote stood at EUR 64.71 at Lang & Schwarz on October 15, 2026 at 6:36 p.m. CEST, up 0.05 percent on Nasdaq versus the prior close.
The further course of trading is shown by the continuously updated real-time quote of Bio-Techne stock.
Bio-Techne market data
- Company: Bio-Techne Corporation
- ISIN: US09073M1045
- Ticker: TECH
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of October 15, 2026, 6:36 p.m. CEST): EUR 64.71
- Change on Nasdaq versus prior close: plus 0.05 percent
- Market capitalization: USD 11.4 billion (as of October 15, 2026)
- 52-week range: USD 43.20-72.69 (as of October 15, 2026)
- Sector / Industry: Healthcare / Biotechnology
- Next earnings date: November 3, 2026
Market context: Market report S&P 500.
